 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...114115116117118119120121122123124...143144» |
- ||||||| Vectibix (panitumumab) / Amgen
Trial completion, Metastases: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2017
P3, N=1010, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. (Pubmed Central) - Apr 13, 2017
Active, not recruiting --> Completed Despite its relatively low accuracy, ITRA might be a useful technique for predicting therapeutic efficacy and selecting for appropriate first-line and second-line anticancer regimens for patients.
- ||||| Nanoplatin (demplatin pegraglumer) / NanoCarrier, Orient Europharma
New P1/2 trial, Combination therapy, Metastases: NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 12, 2017
P1/2, N=80, Recruiting, Sponsor: NanoCarrier Co., Ltd.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. (Pubmed Central) - Apr 12, 2017
Our analysis suggests that EGFR inhibitors have potential efficacy and are reasonably well tolerated in patients with squamous cell anal carcinomas. These findings warrant further evaluation in a large prospective trial.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Apr 11, 2017
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
These findings warrant further evaluation in a large prospective trial. Trial primary completion date: Jun 2016 --> Dec 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. (Pubmed Central) - Apr 9, 2017
PFS ranged from 1.6 to 45 months, with a median duration of 4.6 months, and median overall survival of 5.25 months. Analysis indicates that use of weekly PCC appears to be an effective and well-tolerated treatment option for patients with incurable squamous cell carcinoma of the head and neck, specifically with PS of 0 to 2.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=18, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Analysis indicates that use of weekly PCC appears to be an effective and well-tolerated treatment option for patients with incurable squamous cell carcinoma of the head and neck, specifically with PS of 0 to 2. Recruiting --> Active, not recruiting | N=28 --> 18 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response (clinicaltrials.gov) - Apr 7, 2017
P2, N=28, Completed, Sponsor: Poitiers University Hospital
Recruiting --> Active, not recruiting | N=28 --> 18 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016
- | Biomarker, Review, Journal: Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. (Pubmed Central) - Apr 6, 2017
Instead, downstream, non-canonical pathways related to EGFR may contribute to some aspects of the biological behavior of breast cancer; therefore, the blockade of the receptor could result in sufficient suppression of downstream pathways to inhibit the aggressive behavior of breast cancer. Mechanistic studies to investigate the dynamic interaction between the EGFR pathway and non-canonical pathways are warranted.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Trial completion, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 31, 2017
P1b, N=109, Completed, Sponsor: Bristol-Myers Squibb
Mechanistic studies to investigate the dynamic interaction between the EGFR pathway and non-canonical pathways are warranted. Active, not recruiting --> Completed
- || Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=150, Active, not recruiting, Sponsor: Array BioPharma
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Jul 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy, Metastases: COPAN-ORL06: Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=32, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial primary completion date, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 29, 2017
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Jul 2016 --> Sep 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment open, Metastases: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov) - Mar 28, 2017
P2, N=50, Recruiting, Sponsor: Yale University
Trial primary completion date: Jul 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Mar 27, 2017
P2, N=150, Recruiting, Sponsor: Boston Biomedical, Inc
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Jun 2017
- Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Mar 24, 2017
P1/2, N=13, Suspended, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: Jul 2016 --> May 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jul 2016 --> May 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Biomarker, Trial completion, Enrollment change, Trial primary completion date, FDG PET, Metastases: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=11, Completed, Sponsor: VU University Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jan 2017 --> Jan 2015
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: SWOG S0819: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 20, 2017
P3, N=1546, Active, not recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jan 2017 --> Jan 2015 Trial primary completion date: Feb 2017 --> Aug 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: POSIBA: Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (clinicaltrials.gov) - Mar 20, 2017
P2, N=170, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Feb 2017 --> Aug 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. (Pubmed Central) - Mar 18, 2017
The median TTP with nab-paclitaxel and with prior taxane were similar. This exploratory observation warrants further investigation in prospective studies.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Combination therapy, Metastases: Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 17, 2017
P2, N=112, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
This exploratory observation warrants further investigation in prospective studies. Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2010
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 16, 2017
P2, N=83, Not yet recruiting, Sponsor: Assuntina G. Sacco
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=130, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2010 Trial primary completion date: Jul 2009 --> Aug 2005
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=130, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2009 --> Aug 2005 Active, not recruiting --> Completed
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 14, 2017
P1, N=86, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Mar 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Mar 13, 2017
P3, N=154, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Mar 2017 Not yet recruiting --> Recruiting
- | Enrollment closed, Trial primary completion date, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - Mar 13, 2017
P2, N=50, Active, not recruiting, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Aug 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). (Pubmed Central) - Mar 11, 2017
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Aug 2017 Among patients with stage III resected colon cancer treated with adjuvant FOLFOX, a family history of colorectal cancer did not significantly impact DFS, TTR, or OS outcomes, with the exception of patients with dMMR-expressing tumors.
- | Journal: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. (Pubmed Central) - Mar 11, 2017
Overall, appendiceal cancers have similar patterns in their molecular profile to pancreatic cancers (can we say this, any statistical analysis done?) and have differential expression from colorectal cancers. These findings indicate the need to evaluate patient samples for patterns in marker expression and alteration, in order to better understand the molecular biology and formulate a personalized therapy approach in these difficult to treat cancers (supported by a grant from Caris Life Sciences).
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 9, 2017
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
These findings indicate the need to evaluate patient samples for patterns in marker expression and alteration, in order to better understand the molecular biology and formulate a personalized therapy approach in these difficult to treat cancers (supported by a grant from Caris Life Sciences). Trial primary completion date: Apr 2018 --> Apr 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Mar 8, 2017
P1, N=21, Active, not recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Apr 2018 --> Apr 2019 Trial primary completion date: Jul 2017 --> Jan 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=43, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Jul 2017 --> Jan 2019 Recruiting --> Active, not recruiting
- | carboplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. (Pubmed Central) - Mar 5, 2017
Further research is required regarding the optimal cutoff for positivity and the positive predictive value. Cancer 2016.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 3, 2017
P2, N=106, Completed, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Cancer 2016. Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: INFIELD: Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Mar 1, 2017
P2, N=72, Recruiting, Sponsor: University of Texas Southwestern Medical Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: INTERCEPTOR: Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (clinicaltrials.gov) - Feb 28, 2017
P3, N=282, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Feb 27, 2017
P2, N=33, Active, not recruiting, Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Journal: EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. (Pubmed Central) - Feb 24, 2017
EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF. E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=30, Completed, Sponsor: Samsung Medical Center
E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients. Trial primary completion date: Jan 2014 --> Jan 2015
- |||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 23, 2017
P3, N=760, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Nov 2017 --> Mar 2018
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Feb 23, 2017
P2, N=240, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Nov 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment closed: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Feb 20, 2017
P=N/A, N=140, Active, not recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. (Pubmed Central) - Feb 19, 2017
The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Sutent (sunitinib) / Pfizer
Enrollment change, Trial termination, Combination therapy, Metastases: SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer (clinicaltrials.gov) - Feb 17, 2017
P1/2, N=6, Terminated, Sponsor: Massachusetts General Hospital
This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control. N=44 --> 6 | Active, not recruiting --> Terminated; Slow Accrual
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 15, 2017
P1, N=7, Terminated, Sponsor: University of Pittsburgh
N=44 --> 6 | Active, not recruiting --> Terminated; Slow Accrual Active, not recruiting --> Terminated; drug supply issues
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, PD(L)-1 Biomarker, Metastases: DUCRO-HN: Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (clinicaltrials.gov) - Feb 14, 2017
P2, N=69, Not yet recruiting, Sponsor: Azienda Ospedaliero-Universitaria Careggi
- Tabrecta (capmatinib) / Incyte, Novartis
Trial suspension, Trial primary completion date, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Feb 14, 2017
P1/2, N=13, Suspended, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; drug supply issues Active, not recruiting --> Suspended | Trial primary completion date: Jan 2018 --> Jul 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change: A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (clinicaltrials.gov) - Feb 11, 2017
P2, N=22, Completed, Sponsor: University Hospital, Ghent
Active, not recruiting --> Suspended | Trial primary completion date: Jan 2018 --> Jul 2016 Recruiting --> Completed | N=18 --> 22
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Feb 11, 2017
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed | N=18 --> 22 Trial primary completion date: Jun 2017 --> Jul 2015